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Abstract: Increasing evidence highlights bipolar disorder as being associated with impaired 
neurogenesis, cellular plasticity, and resiliency, as well as with cell atrophy or loss in specific 
brain regions. This has led most recent research to focus on the possible neuroprotective effects 
of medications, and particularly interesting findings have emerged for lithium. A growing body 
of evidence from preclinical in vitro and in vivo studies has in fact documented its neuropro-
tective effects from different insults acting on cellular signaling pathways, both preventing 
apoptosis and increasing neurotrophins and cell-survival molecules. Furthermore, positive 
effects of lithium on neurogenesis, brain remodeling, angiogenesis, mesenchymal stem cells 
functioning, and inflammation have been revealed, with a key role played through the inhibi-
tion of the glycogen synthase kinase-3, a serine/threonine kinase implicated in the pathogenesis 
of many neuropsychiatric disorders. These recent evidences suggest the potential utility of 
lithium in the treatment of neurodegenerative diseases, neurodevelopmental disorders, and 
hypoxic–ischemic/traumatic brain injury, with positive results at even lower lithium doses than 
those traditionally considered to be antimanic. The aim of this review is to briefly summarize 
the potential benefits of lithium salts on neuroprotection and neuroregeneration, emphasizing 
preclinical and clinical evidence suggesting new therapeutic potentials of this drug beyond its 
mood stabilizing properties.
Keywords: bipolar disorder, GSK-3, neurodegeneration, neurogenesis, neurodevelopmental 
disorders
Introduction
Lithium is still considered a first-line therapy for both the acute and long-term treatment 
of bipolar disorder (BD),1 due to its well-documented antimanic,2 antisuicidal,3–5 and 
prophylactic properties6,7 and the adjunctive treatment of major depression.8 Although 
all potential mechanisms underlying lithium mood-stabilizing properties have not 
yet been completely clarified, a growing body of evidence has recently suggested the 
potential benefits on neuroprotection and neuroplasticity of this drug.
There is now evidence that BD is related to progressive impairment in neurocog-
nitive functioning, as well as to regional impairments in neuroplasticity, cellular 
resilience, and adult neurogenesis.9–15 Morphometric brain-imaging studies, in fact, 
have documented cell atrophy or loss in several brain areas, especially prefrontal 
regions (eg, anterior cingulated and subgenual prefrontal cortex), as well as hip-
pocampal volume decrease and smaller amygdalar volumes, in both adult and pediatric 
BD patients compared with healthy control subjects.16–20 Such regional brain abnor-
malities have been suggested to play a role in the pathophysiology of BD, giving rise 
to the debate as to whether they derive from neurodevelopmental, neurodegenerative, 
or combined deficits.10,21,22
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Consistently, most recent research studies have 
progressively focused on the possible neuroprotective effects 
of psychotropic medications for BD, and interesting results 
have particularly emerged for lithium salts.
This review aims to briefly summarize the most recent 
evidence on lithium benefits beyond its mood-stabilizing 
properties, with particular attention to its potential effects on 
neuroprotection and neuroregeneration, in both preclinical 
and clinical studies, highlighting possible new therapeutic 
potentials of this old drug.
Methodology
MEDLINE/PubMed (1985–2015) articles published in Eng-
lish were identified using the following keyword combina-
tions: lithium, bipolar disorder, neuroprotection, neurogenesis, 
neurodegenerative disorders, neurodevelopmental disorders, 
autism, and glycogen synthase kinase-3 (GSK-3).
Neuroimaging outcomes of lithium 
treatment in BD
Several neuroimaging studies in BD patients have shown lith-
ium treatment to increase cortical gray matter volumes, espe-
cially in the anterior cingulate and in the paralimbic cortices 
that are implicated in attention, motivation, and emotional 
modulation, as well as the hippocampus volume.18,19,23–30 
The association between lithium treatment and gray matter 
volume increase has been demonstrated regardless of the 
mood state, the diagnostic subtype, and presence or absence 
of concomitant medications.31
However, the nature and mechanisms of this positive asso-
ciation remain to be clarified in terms of whether these may 
depend on a direct effect of lithium on brain structures, through 
its action on the biochemical pathways involved in neurogen-
esis and apoptosis, or whether these are an epiphenomenon of 
the acute or prophylactic lithium efficacy. In a neuroimaging 
study using voxel-based morphometry, Hajek et al32 recently 
demonstrated that the positive association between lithium 
treatment and increase in hippocampal volume seems to be 
independent of long-term treatment response, as occurred 
also in those BD patients on lithium who reported episodes 
of illness while on treatment. Additional evidence comes 
from studies using quantitative proton magnetic resonance 
spectroscopy to measure cortex levels of N-acetyl-aspartate 
(NAA), a marker of neuronal viability and/or functioning, in 
BD patients. Chronic lithium treatment was found to increase 
NAA levels in both BD patients and healthy controls.33,34 In 
a study comparing two groups of BD patients with a similar 
illness burden but differing lithium levels of exposure with 
respect to healthy control subjects, prefrontal NAA levels 
were found to be lower in patients without or with limited life-
time exposure to lithium compared with those under ongoing 
lithium treatment or controls.35 Furthermore, these two latter 
groups of participants did not differ in terms of NAA levels; 
a negative correlation between prefrontal NAA and duration 
of illness was found only in the group of patients not exposed 
or with limited exposure to lithium. This lithium effect on 
NAA levels was suggested to be related to the expansion of 
neuropil content, accordingly with the evidence of lithium-
induced increase in gray matter volumes.
Since the neuroprotective effects of lithium on brain struc-
tures have been shown even in healthy subjects and appear to 
be independent from prophylactic treatment response, Hajek 
and Weiner31 recently hypothesized that lithium treatment 
might help maintain brain health even in patients without 
BD and could possibly demonstrate disease-modifying proper-
ties in neurodegenerative disorders. In this regard, Forlenza et 
al36 evaluated whether the neurobiological properties of lithium 
reflect in increased regional brain glucose metabolism with the 
aid of 18 fluorine-fluoro-2-deoxy-d-glucose positron emission 
tomography in a sample of 19 older adults with amnestic mild 
cognitive impairment. The exposure to subtherapeutic levels 
of lithium carbonate (0.25–0.5 mEq/L) for 4 years in 12 of 
these patients was associated with a significant reduction in 
the glucose uptake in several clusters of the cerebellum and 
in both hippocampi, in comparison with matched controls. 
These results do not support the hypothesis that lithium might 
increase regional brain metabolism as a consequence of its neu-
rotrophic effects. However, none of the patients in the sample 
reported any clinically relevant signs of lithium toxicity. Future 
studies with appropriate methodology are needed to address 
the clinical implications of these findings, particularly in light 
of the potential use of lithium as a disease-modifying treatment 
approach for certain neurodegenerative disorders.
Neuroprotective effects of lithium: 
preclinical evidence and molecular 
mechanisms
A number of preclinical in vitro and in vivo studies have 
documented a neuroprotective effect of lithium against 
neuronal injury caused by various noxious insults, mainly 
acted by preventing apoptosis and increasing neurotrophins 
excretion.9,13,37–40 Additional neuroprotective mechanisms 
include the modulation of autophagy and oxidative stress 
and the upregulation of mitochondrial function.41 Further-
more, lithium appears to reduce proinflammatory status, by 
modulating inflammatory activity.42–46
In particular, lithium has been shown to inhibit GSK-3α 
and GSK-β; upregulate neurotrophins and cell survival 
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molecules (eg, B-cell lymphoma 2 [Bcl-2], brain-derived 
neurotrophic factor [BDNF]/tropomyosin receptor kinase B 
[TrkB], cyclic adenosine monophosphate-responsive element-
binding protein [CREB], heat shock protein 70 [Hsp70], 
and β-catenin); downregulate proapoptotic activities (eg, 
excitotoxicity, p53, Bcl-2-associated X protein, caspase, 
cytochrome c release, β-amyloid peptide production, and 
tau hyperphosphorylation); inactivate N-methyl-d-aspartate 
(NMDA) receptors; inhibit inositol monophosphatase (IMP); 
and activate the phosphatidylinositol-3-kinase (PI3K)/pro-
tein kinase B (Akt) cell survival pathway.38,47–56 Such a wide 
range of intracellular responses involved in the neuropro-
tective action of lithium may be secondary to its inhibitory 
effect on two key targets, namely, GSK-3β and IMP. The 
modification of these intracellular pathways is relevant to the 
understanding of the pathogenesis of certain neuropsychiatric 
and neurodegenerative diseases (Figure 1).41
Lithium inhibition of the GSK-3, both direct binding to 
the magnesium-sensitive site of the enzyme and indirect, 
enhancing the phosphorylation of specific N-terminal serine 
residues, has been demonstrated to play a major role for 
lithium neuroprotective functions.53,57 There is also evidence 
of lithium modulation of GSK-3β expression at the transcrip-
tional level in a dose-dependent manner, as a consequence 
of the inhibition of mRNA transcription.58 The GSK-3 is a 
serine/threonine kinase that regulates several cellular pro-
cesses, such as glycogen synthesis, gene transcription, synap-
tic plasticity, cell apoptosis, cellular structure and resilience, 
and the circadian cycle.53 Its activation functionally inhibits 
CREB, β-catenin, and other survival-promoting transcrip-
tion factors. Conversely, its inactivation has been suggested 
to promote neuronal survival and to improve cell structural 
stability directly influencing gene transcription.50,59–61 In 
addition, GSK-3 directly regulates several neurotransmitter 
systems, including serotonergic, dopaminergic, cholinergic, 
and glutamatergic.62,63 Because of changes in these neu-
rotransmitter systems, dysregulated GSK-3 has been linked 
to depression, BD, and schizophrenia.
The GSK-3 is also implicated in the pathogenesis of many 
neuropsychiatric disorders, such as Alzheimer’s disease 
(AD), Parkinson’s disease (PD), spinocerebellar ataxia type 1 
(SCA1), multiple sclerosis (MS), fragile X syndrome (FXS), 
Down syndrome (DS), traumatic brain injury (TBI), and 
ischemic stroke.40,64–72 It represents the predominant kinase 
in the brain responsible for the aberrantly hyperphosphory-
lation of the tau protein and also plays a major role in the 
amyloid deposition affecting the core pathological features 
of AD.68,73,74 Therapeutic concentrations of lithium, through 
the inhibition of the GSK-3, have been demonstrated to 
significantly lower the levels of the tau phosphorylation in 
living cells and neurons, thus reducing the levels of aggre-
gated, insoluble tau.75,76 Further, they have been demonstrated 
to block both the production of amyloid-beta peptides, by 
interfering with the amyloid precursor protein cleavage, and 
the accumulation of amyloid-beta peptides in the brain of 
mice that overproduce amyloid precursor protein.76
Both the downregulation of GSK-3β and the elevated 
β-catenin, two components of the canonical Wnt signaling 
pathway, were implicated in adult hippocampal progeni-
tor cell proliferation triggered by lithium treatment.77 The 
GSK-3 may regulate cognitive functions by influencing the 
components of synaptic plasticity that are long-term depres-
sion (LTD) and long-term potentiation (LTP), involved in the 
regulation of learning and memory.78,79 This kinase is a key 
regulator of the balance between pro- and anti-inflammatory 
cytokine production in both the peripheral and the central 
nervous system and influences T-cell proliferation, differ-
entiation and survival, so that its inhibition determines anti-
inflammatory effects.42 Administration of GSK-3 inhibitors 
in mice has been shown to control several inflammatory and 
immune conditions in both the periphery and the central 
nervous system.42 The inhibition of GSK-3, as well as its 
genetic inactivation, has also produced antidepressive-like 
behaviors and strong anti-manic-like effects in a wide range 
of animal models.80–87 According to this, a deficient inhibi-
tion of GSK-3 has been linked to an increased susceptibil-
ity to mood disorders.87 The finding that transgenic mice 
overexpressing β-catenin demonstrate behavioral changes 
comparable to those observed after lithium administration 
gives further support to the notion that the therapeutic effects 
of lithium are mediated by the inhibition of GSK-3 and the 
consequent increase in β-catenin levels.88
As mentioned earlier, chronic inhibition of GSK-3 may 
mediate the neuroprotective effects of lithium in the long 
term by stimulating the gene and protein expression of 
antiapoptotic factors (eg, CREB, nuclear factor kappa-light-
chain-enhancer of activated B-cells [NF-κB], Bcl-2, BDNF, 
β-catenin).81,89 In particular, preclinical studies in rat brains 
and human neurons showed chronic lithium administration to 
induce prominent neuroprotective and neurotrophic proteins, 
such as Bcl-2 and BDNF.48,51,90,91 The Bcl-2 not only is a major 
antiapoptotic protein but also stimulates axonal regeneration 
following injury.55,92 The upregulation of Bcl-2 by lithium has 
been postulated to account for the neuropil expansion mani-
festing as an increase in gray matter volume in the human 
brain.18,55 Interestingly, also the chronic administration of low 
lithium doses, producing plasma levels of ~0.35 mM, showed 
to robustly increase Bcl-2 levels in the frontal cortex and 
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hippocampus of rats.93 The BDNF is a neurotrophin playing 
a critical role in cortical development, synaptic plasticity, 
neuronal differentiation, and survival.21,94 It has been dem-
onstrated to be involved in the pathophysiology of mental 
disorders, with decreased peripheral levels being reported 
during the acute manic, mixed and depressive episodes of 
BD,95–99 as well as in patients with chronic post-traumatic 
stress disorder (PTSD)100 or schizophrenia.101 Treatment with 
therapeutic concentrations of lithium and valproic acid is 
known to selectively increase the levels of exon IV-containing 
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Figure 1 A schematic illustration of neurotrophic and neuroprotective mechanisms targeted by lithium.
Abbreviations: ↓, decrease; ↑, increase; AC, adenylyl cyclase; AD, Alzheimer’s disease; Akt, protein kinase B; ALS, amyotrophic lateral sclerosis; AP-1, activator protein-1; 
BBB, blood–brain barrier; Bcl-2, B-cell lymphoma 2; BDNF, brain-derived neurotrophic factor; cAMP, cyclic adenosine monophosphate; COX-2, cyclooxygenase-2; CReB, 
cAMP-responsive element-binding protein; DAG, diacylglycerol; eRK, extracellular-regulated kinase; GDNF, glial cell line-derived neurotrophic factor; GSK-3, glycogen 
synthase kinase-3; HD, Huntington’s disease; HSF, heat shock factor; Hsp70, heat shock protein 70; iMP, inositol monophosphatase; iP3, inositol 1,4,5-triphosphate; MAP, 
mitogen-activated protein; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; NGF, nerve growth factor; NMDAR, N-methyl-d-aspartate receptor; PD, 
Parkinson’s disease; Pi3K, phosphatidylinositol-3-kinase; PKA, protein kinase A; PKC, protein kinase C; veGF, vascular endothelial growth factor.
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BDNF mRNA and the activity of BDNF promoter IV,94 as 
well as to induce the subsequent activation of BDNF recep-
tor (TrkB) in cultured rat cortical neurons.38,51 Consistently, 
elevated BDNF levels were reported in the hippocampus and 
in the frontal and temporal cortex of rat brains after chronic 
treatment with lithium and valproate.90,102–104 Clinical studies 
showed lithium to restore and even increase BDNF levels 
in patients with BD,105 and a relationship between lithium 
prophylactic efficacy and such levels was reported in a 
sample of euthymic bipolar patients.106 Lithium has also been 
shown, in in vivo and in vitro preclinical studies, to increase 
the expression of other neurotrophins involved in neuronal 
survival and plasticity, such as the nerve growth factor, the 
glial cell line-derived neurotrophic factor, and the vascular 
endothelial growth factor (VEGF).107–112
Some evidence demonstrates that lithium produces neu-
rotrophic effects affecting cyclic adenosine monophosphate-
mediated signal transduction. This action is mainly exerted 
elevating basal adenylyl cyclase activity, but also reducing 
receptor-stimulated responses, as demonstrated in both pre-
clinical and clinical studies.60,113,114 The physiologic effects 
of cyclic adenosine monophosphate are primarily mediated 
by the activation of protein kinase A, one of whose major 
targets in the central nervous system is CREB, a transcription 
factor that plays a major role in mediating adaptive responses 
at glutamatergic synapses, as well as in the neuroprotective 
effects of neurotrophins and in long-term neuroplasticity.60 
Indeed, the activation of the extracellular-regulated kinase 
(ERK)/mitogen-activated protein kinase (MAPK) pathway 
via CREB initiates the transcription of BDNF and also 
induces Bcl-2 expression. At therapeutically relevant con-
centrations, both lithium and valproate have been shown to 
activate the ERK/MAPK cascade in human neuroblastoma 
SH-SY5Y cells in vitro,115 as well as in hippocampus and 
frontal cortex areas of the rodent brain,103 thus producing 
neurotrophic effects.
Experimental studies also found chronic lithium admin-
istration to provide nearly complete protection against 
glutamate-induced, NMDA receptor (NMDAR)-mediated 
excitotoxicity in primary cerebellar, cerebral cortical, and 
hippocampal neuronal cultures.52,116,117 Excessive NMDA 
throughput has been, in fact, hypothesized to be involved in 
stress-induced hippocampal atrophy and implicated in the 
pathogenesis of various neurodegenerative diseases.38,116,118 
This neuroprotective effect was obtained also with low 
lithium doses (0.1–0.6 mM) and was associated with the 
inhibition of NMDAR-mediated calcium influx.38,52 Addi-
tional evidence indicates that the lithium mechanism of action 
results from the attenuation of constitutive phosphorylation of 
the N-methyl D-aspartate receptor subtype 2B (NR2B) sub-
unit of the NMDAR, which is catalyzed by Fyn, a member of 
the Src tyrosine kinase family.52,119 Brain ischemia is known 
to increase Src-mediated tyrosine phosphorylation of NR2A, 
as well as the interaction of NR2A with Src and Fyn, which 
is mediated by postsynaptic density protein 95.120,121 Lithium 
was shown to reduce NR2A phosphorylation and its postsyn-
aptic density protein 95-mediated interactions with Src and 
Fyn in rat hippocampus following cerebral ischemia.122 Fur-
thermore, chronic lithium treatment antagonizes glutamate-
induced activation of c-Jun-N-terminal kinase, p38 kinase, 
and activator protein-1 transcription factor binding, which 
has a major role in cytotoxicity, and suppresses glutamate-
induced decrease of the CREB phosphorylation in cultured 
cerebellar granule neurons.38,54
According to the inositol depletion hypothesis,123 the 
phosphatidylinositol (PI) pathway has also been proposed 
as a major target through which lithium could exert its 
therapeutic effects. As with GSK-3, lithium directly inhibits 
IMP and inositol polyphosphate-1 activity by the competitive 
displacement of Mg2+ from the catalytic site of the enzyme.56 
The inhibition of IMP and inositol polyphosphate-1 prevents 
the reuptake of inositol, leading to depletion of intracellular 
levels and subsequent inhibition of the phosphoinositol 
cycle.41 The decrease in free-myoinositol levels and, subse-
quently in the production of diacylglycerol induced by the 
inhibition of IMP, has the downstream effect of decreasing 
protein kinase C levels and activity.60 The reduction of pro-
tein kinase C levels and activity was demonstrated in cells 
as well as in rodents after chronic lithium treatment, with 
implication on neuroplastic events.124 Moreover, the inhibi-
tion of protein kinase C has been suggested as a mechanism 
producing antimanic effects.60,125
More recently, the ability of lithium to inhibit the activity 
of IMP and subsequently decrease inositol 1,4,5-triphosphate 
levels was identified as a novel mechanism for inducing 
autophagy.126–129 Autophagy, a physiological process for 
degrading cytoplasmic proteins or organelles, has been recog-
nized as a principal response to cellular stress and an important 
regulator of neuronal function and survival.129 It is believed to 
be particularly beneficial as a “quality control” process in neu-
rodegenerative disorders characterized by the accumulation of 
misfolded disease-causing proteins (eg, AD, PD, Huntington’s 
disease [HD], amyotrophic lateral sclerosis [ALS]).130–132
The inhibition of the two main targets of lithium, IMP, 
and GSK-3β, shows opposite effects on autophagy, that is 
modulated in a dose-dependent manner: lithium induces 
inhibition of IMP at lower doses (Ki ≈0.8 mM), enhancing 
autophagy,126 while it induces inhibition of GSK-3β at higher 
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doses (Ki ≈2 mM), downregulating autophagy via activation 
of mammalian target of rapamycin (mTOR).118,133
The inhibition of PI3K, a kinase involved in cell survival 
pathways, has been found to block the activity of the anti-
apoptotic serine-threonine Akt-1 kinase causing neuronal 
death, and this apoptotic pathway was prevented by chronic 
lithium exposure increasing PI3K activity in primary cerebel-
lar neurons.47 Acute lithium exposure also protected cortical 
neurons via a PI3K-mediated increase in intracellular calcium 
through the phospholipase Cγ pathway.134 Furthermore, 
in cultured human neuroblastoma SHSY5Y cells, lithium 
treatment ameliorated HIV-gp120-mediated toxicity via the 
PI3K/Akt pathway.135
Recent evidence suggests that lithium treatment enhances 
the mitochondrial respiratory rate, reduces oxidative stress, 
protects DNA against damage from oxidative stress, and 
modulates calcium influx in the mitochondria.60,136–139 Both 
lithium treatment of acute mania and clinical improvement of 
depressive symptoms after lithium administration were asso-
ciated with a reduction of pro-oxidative stress markers.12,140 In 
addition, lithium showed to affect oxidative stress in healthy 
subjects increasing antioxidative and reducing pro-oxidative 
markers.141 Nitric oxide (NO) is one of the most important 
intracellular second messenger activated by oxidative stress 
status. NMDAR activation can increase the activation of NO 
synthase, the enzyme responsible for NO production, and 
lithium treatment has recently been suggested to regulate 
this molecular mechanism.142
Besides promoting neuronal survival after damage, lithium 
has been reported to promote hippocampal neurogenesis. In 
mammals, new neurons continue to be produced throughout 
adult life in the subventricular zone and the hippocampal den-
tate gyrus (DG).143 Compared with preexisting mature dentate 
granule cells, newborn neurons exhibit peculiar electrophysi-
ological features (ie, increased intrinsic excitability, enhanced 
synaptic plasticity, reduced sensitivity to GABAergic inhi-
bition, and lower threshold for the induction of LTP) that 
showed to be essential for hippocampal function in the DG, an 
area primarily involved in cognitive processes.144–147 Impaired 
adult neurogenesis has been observed in various models rel-
evant to neuropsychiatric disorders (ie, BD, major depression, 
schizophrenia, and AD) and neurodevelopmental disorders 
(ie, FXS and DS).143,148–152 Recent data have correlated low 
proliferation and differentiation capacities of adult hippocam-
pal stem cells with memory dysfunction,152 suggesting adult 
neurogenesis might be a promising therapeutic target for 
disease-associated cognitive impairment. Several preclini-
cal studies showed lithium to stimulate the proliferation and 
differentiation of neuronal progenitor cells, as well as their 
maturation and functioning.153–158
Lithium in neurodegenerative 
diseases
The risk of cognitive impairment and dementia has been 
reported to be higher in patients with BD than in the gen-
eral population, correlating with the duration of illness, as 
well as with the number of illness episodes, especially the 
depressive ones, and the degree of impairment.159,160 Both 
preclinical and clinical studies have produced new evidence 
of lithium benefits in terms of preventing dementia through 
its action on GSK-3,66,161 leading to its investigation also in 
neurodegenerative disorders.
In a case–control study that compared AD prevalence 
rates among elderly euthymic bipolar patients on chronic 
lithium therapy with respect to those of similar patients who 
had not been treated with lithium recently, Nunes et al162 
showed lithium to be able to reduce AD prevalence to 
levels comparable with those of the general elderly popula-
tion. Since the number of previous affective episodes was 
equivalent between the two patient groups, this putative neu-
roprotective effect was related to the intrinsic biological brain 
effects of lithium. Findings from two other observational 
studies corroborated the reduced risk of AD in BD patients 
on long-term lithium treatment.163,164 Conversely, this posi-
tive effect was not shown in patients taking anticonvulsants, 
antidepressants, or antipsychotics.164
Evidence of benefits of lithium in preventing cognitive 
impairment in nonbipolar AD patients is mixed. A small, 
open-label study found no cognitive benefits of lithium 
carbonate administration for up to 1 year to 25 patients 
with mild to moderate AD.165 In a randomized, single-blind, 
placebo-controlled, 10-week study of 71 patients with a mild 
form of AD, treatment with lithium at therapeutic levels 
(0.5–0.8 mmol/L) showed no significant benefits on either 
cognitive performance or cerebrospinal fluid concentrations 
of disease-related biomarkers.166 On the contrary, in a subset 
of a greater sample recruited for a randomized, single-blind, 
placebo-controlled, parallel-group 10-week multicenter 
study, investigating the efficacy of lithium treatment in early 
AD patients, a significant increase of BDNF serum levels was 
shown.167 In a 12-month, single-center, randomized, double-
blind, placebo-controlled study, carried out on subjects with 
amnestic mild cognitive impairment,168 chronic lithium 
administration was associated with a significant decrease 
in cerebrospinal fluid concentrations of P-tau and better 
performances on the cognitive subscale of the AD assessment 
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scale and in attention tasks. The reduction of the cerebrospinal 
fluid P-tau was found in subjects with amnestic mild cogni-
tive impairment who did not convert to AD, suggesting that 
this disease-modifying effect of lithium may be a useful 
parameter for predicting its property to prevent, or at least 
to delay, the progression from pre-dementia stage to clinical 
dementia. Lithium was administered at subtherapeutic levels 
(serum levels of 0.2–0.4 mmol/L), which resulted safe and 
well tolerated. In contrast with previous studies that failed to 
find a significant effect of lithium either on cognition or on 
AD-related biomarkers,165,166 this study included individuals 
without a manifest form of dementia. Finally, a more recent 
intriguing trial found beneficial effects of a lithium micro-
dose of 300 μg administered once daily to AD patients for 
15 months in preventing cognitive loss.169 Overall, findings 
from clinical samples highlight preferential benefits of lith-
ium in dementia prevention in patients with mood disorders 
and mild cognitive impairment, suggesting that long-term 
lithium treatment may have disease-modifying properties on 
the core pathophysiologic features of AD, mostly if started 
at the earlier stages of the disease process.41,168,170
Lithium inhibition of the GSK-3 has also been hypoth-
esized to produce neuroprotective effects in other neurode-
generative disease models, such as PD, tauopathies, HD, 
ALS, SCA1, and MS.10,40,41,65,171–173 Whether these pharma-
codynamic properties of lithium can be translated into neu-
rodegenerative diseases modifying effects in human subjects 
is a critical question.174
Several preclinical studies have suggested that lithium 
can prevent neurodegeneration in vitro and in vivo models 
of PD.67,175–177 Therapeutic concentrations of lithium have 
been shown to facilitate clearance of the mutant form of 
α-synuclein, one of the major components of Lewy bodies, 
inducing autophagic processes.126,177 Other preliminary data 
suggest that the antioxidant effects of lithium may be beneficial 
for PD by preventing free radical damage of dopaminergic 
neurons.171 In a mouse model of PD, mice were fed with a 
diet containing 1.1, 2.2, 3.3, and 4.4 g/kg lithium chloride for 
4 weeks prior to the injection of the parkinsonism neurotoxin 
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).178 
The 3.3 g/kg lithium diet gave serum level value very similar to 
what is observed in lithium therapy in man and the 4.4 g/kg diet 
gave serum level values well above this. Results of this study 
showed chronic lithium diet to prevent the decrease of dop-
amine levels, as well as of tyrosine hydroxylase activity and 
protein levels in striatum. A direct relationship was established 
between serum lithium concentration and the prevention of 
MPTP-induced depletion of striatal dopamine. MPTP-treated 
mice showed significantly decreased striatal Bcl-2 levels, as 
opposed to increased Bcl-2-associated X protein levels, and 
lithium treatment was found to prevent such changes. Chen et 
al179 demonstrated that 6-hydroxydopamine (6-OHDA), a PD 
mimetitc, activates GSK-3β in cultured human neuroblastoma 
SH-SY5Y cells, as well as in cultures of rat cerebellar granule 
neurons, inducing neuronal death. Lithium and other specific 
GSK-3β inhibitors showed to protect SH-SY5Y cells and 
cerebellar granule neurons from 6-OHDA-induced apoptosis. 
However, other studies have presented conflicting results, 
showing lithium to fail in the protection of dopaminergic 
neurons from 6-OHDA-induced degeneration in the substantia 
nigra of rats.41,180 To date, no clinical trials have been conducted 
in human patients to test these findings.
HD is a progressive, autosomal dominant neurodegen-
erative disorder caused by an expanded CAG repeats at 
exon 1 of the huntingtin (Htt) gene resulting in the aggregate 
formation of mutant huntingtin protein (mHtt).181 Clinical 
presentation of HD includes psychiatric disturbances such as 
significant changes in personality or mood, cognitive decline 
that may gradually lead to dementia, and motor dysfunction 
characterized by chorea. Pathological processes and path-
ways involved in the development of HD include selective 
death/atrophy of medium-sized spiny neurons within the 
striatum and, to a lesser extent, loss of neuros in the cortex; 
dysregulation of cellular autophagy; mitochondrial dys-
function; decreased neurotrophic and growth factor levels; 
and transcriptional dysregulation and aberrant epigenetic 
modifications.181 Presently no cure exists to treat or halt the 
progression of this devastating disease. On the basis of accu-
mulating evidence indicating the promising role of lithium 
for the treatment of neurodegenerative diseases, its use has 
been investigated in cellular and animal HD models. Pre- and 
posttreatment with lithium chloride (2.5–5.0 mM) protected 
nonneuronal and neuronal cells transfected with mutant Htt 
exon 1 fragment containing 74 CAG repeats, increased cell 
survival, and decreased aggregate formation compared with 
nontreated group in both the cell types.65 In a rat model of 
HD induced by quinolinic acid (QA) unilateral infusion into 
the striatum, subcutaneous injection of lithium chloride for 
16 days prior to QA infusion significantly reduced the size of 
the excitotoxicity-induced striatal lesion. The lithium-elicited 
neuroprotective action was associated with an increase 
in Bcl-2 protein levels.182 A subsequent study assessed 
the ability of lithium to reduce neurodegeneration and to 
stimulate cell proliferation in a rat model of HD induced by 
QA. LiCl (0.5–3.0 mEq/kg) was injected subcutaneously 
24 hours before and 1 hour after QA infusion. Seven days 
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after QA injection, lithium significantly diminished the loss 
of neurons, prevented apoptosis by attenuating QA-induced 
DNA damage and caspase-3 activation, upregulated Bcl-2 
levels, and promoted neuronal and astroglial progenitor cell 
proliferation.183 Combined treatment with therapeutic levels 
of lithium (1.0 mM) and valproate (0.5 mM) was found to be 
more effective than treatment with either drug alone in upreg-
ulating mRNA and protein levels of BDNF, as well as other 
neuroprotective proteins such as Hsp70 in the striatum and 
cortex, in two models of transgenic HD mice. Cotreatment 
with lithium and valproate also more effectively alleviated 
spontaneous locomotor deficits and depressive-like behav-
iors and markedly prolonged median survival of transgenic 
mice, compared with monotreatment.65 Lithium use was 
also investigated in clinical trials of HD. Two recent clinical 
studies demonstrated lithium’s mood-stabilizing effects in 
HD patients of varying ages and duration of illness.184,185 The 
addition of lithium to tetrabenazine eliminated suicidal symp-
toms in all patients and improved depressive symptomts.185 
Moreover, it prevented the progression of chorea in three 
of these patients.184 Despite these findings, clinical trials 
reported no benefits of lithium administration on improving 
choreiform movements.181 However, it is important to notice 
that these studies may be inconclusive due to the method-
ological limitations and small sample size.
Evidence of the neuroprotective effects of lithium from 
ALS models is inconsistent.186–190 In mouse models of ALS, 
treatment with either lithium alone or in combination with 
an antioxidant has been shown to improve motor function 
and slow down disease progression.189,190 The mainly hypoth-
esized mechanism for such improvement was the stimulation 
of autophagy by lithium.186,191 Combined treatment of ALS 
mice with lithium and valproate produced a greater and more 
consistent effect in delaying the onset of disease symptoms, 
prolonging the lifespan, and decreasing the neurological 
deficit scores, in comparison with monotreatment with either 
drug.191 On the contrary, some preclinical studies reported 
no benefits of lithium administration in improving disease 
symptoms.187,188 In a small, 15-month pilot study on random-
ized ASL patients, a significant effect on disease progression 
and survival was reported in the lithium plus riluzole group 
(lithium plasma levels ranging from 0.4 to 0.8 mEq/L) com-
pared with the riluzole only.186 A subsequent randomized, 
double-blind, placebo-controlled trial showed no benefits of 
lithium (serum levels maintained between 0.4 and 0.8 mEq/L) 
plus riluzole combination in slowing down the progression 
of ALS comparing with riluzole alone.192 More recently, 
a multicenter, double-blind, randomized, placebo-controlled 
trial (lithium carbonate in ALS trial) was designed to test the 
hypothesis that lithium may improve survival rates in ALS.193 
Oral doses of lithium carbonate (mean serum levels rang-
ing from 0.4 to 0.8 mmol/L) or placebo were continuously 
administered for 18 months. Lithium treatment was shown 
to be safe, but study results did not support any evidence of 
lithium benefit on survival compared to placebo.194,195
Results from preclinical studies also suggest that lithium 
may be useful for therapeutic intervention in autoimmune 
and inflammatory diseases, such as MS, the most common 
inflammatory demyelinating disease of the central nervous 
system. Lithium pretreatment at therapeutic doses in experi-
mental autoimmune encephalomyelitis models not only 
markedly suppressed the clinical symptoms of experimental 
autoimmune encephalomyelitis but also greatly reduced 
demyelination, microglia activation, and leukocyte infiltra-
tion in the spinal cord.172
Finally, lithium efficacy was tested in a knock-in mouse 
model of SCA1 (Sca1[154Q/2Q] mice) that replicates many 
features of the human disease, a dominantly inherited neu-
rodegenerative disorder characterized by progressive motor 
and cognitive dysfunction.173 In this study, Sca1(154Q/2Q) 
mice and their wild-type littermates were fed either regu-
lar chow or chow that contained 0.2% lithium carbonate. 
Dietary lithium carbonate supplementation resulted in the 
improvement of motor coordination, learning, and memory 
in Sca1(154Q/2Q) mice, both presymptomatically and after 
symptom onset. Neuropathologically, lithium treatment 
improved hippocampal dendritic arborization in mutant 
hippocampal pyramidal neurons.
Lithium in neurodevelopmental 
disorders
Parallel to research on neurodegenerative disorders, lithium 
potential neuroprotective functions have been explored in 
neurodevelopmental disorders, with the strongest evidence 
emerging in preclinical studies of FXS, the most commonly 
inherited form of mental retardation and autism. FXS is 
caused by suppressed expression of the fragile X mental 
retardation protein,196 an RNA-binding translational regula-
tor important for establishing and maintaining functional 
neuronal networks.197,198 An altered synaptic plasticity, with 
pathologically enhanced metabotropic glutamate receptor 
(mGluR)-dependent LTD in the hippocampal CA1 neurons 
and deficits in NMDAR-dependent LTP at medial perforant 
path synapses in the DG, has been detected in mouse models 
of FXS (FX mice),199–201 suggesting enhanced mGluR sig-
naling to be a major cause of this syndrome.202 According 
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to this, the inhibition of mGluR5 has been shown to reverse 
several behavioral and morphological phenotypes, including 
cognitive deficits, in both developing and adult FX mice.203,204 
Overall, these findings established a clear link between 
synaptic dysfunction and learning deficits in FXS.
Furthermore, following the discovery that the GSK-3 
activity and the mGluR5 signaling were coordinately elevated 
in the hippocampus, striatum, and cerebral cortices of FX 
mice, with the inhibition of mGluR5 leading to the inhibi-
tion of GSK-3, research studies investigated this kinase as a 
therapeutic target for the treatment of FXS.205 According to 
this, GSK-3 has been identified as a bidirectional regulator 
of NMDAR-dependent synaptic plasticity, as LTP induction 
requiring the inhibition of GSK-3β, while GSK-3β activity 
is required for LTD induction.206,207
Lithium inhibition of GSK-3 was found to revert the 
altered phenotypes of FX mice, that is, to attenuate enhanced 
mGluR-mediated LTD, to ameliorate locomotor hyperac-
tivity, audiogenic seizure hypersensitivity, increased spine 
density, excess protein synthesis, social behavior deficits, 
deficient passive avoidance learning and synaptic plasticity, 
and to normalize impaired hippocampus-dependent cogni-
tive tasks.205,208–214 To the best of our knowledge, only one 
small open-label trial has been conducted in FXS patients,215 
showing lithium treatment titrated to levels of 0.8–1.2 mEq/L 
to improve cognitive performance modifying the disrupted 
regulation of group 1 metabotropic glutamate receptor 
(mGluR and mGluR5)-dependent translation in dendrites.
Neuropathological alterations have also been described 
in autism spectrum disorders (ASDs). A preclinical study 
on neonatal rats isolated from their mother showed apparent 
autistic-like symptoms, such as social deficits, excessive 
repetitive self-grooming behavior, and increased anxiety- 
and depressive-like behaviors that were accompanied by 
impaired adult hippocampal neurogenesis, and enhanced 
basal inhibitory synaptic transmission in the hippocampal 
CA1 pyramidal neurons.216 Chronic lithium administration 
was effective in ameliorating these pathological changes, 
completely overcoming autistic-like behaviors, and restoring 
adult hippocampal neurogenesis and the balance between 
excitatory and inhibitory synaptic activities to physiological 
levels, supporting the use of lithium as a potential therapeutic 
agent against ASDs. Interestingly, two recent case studies 
described the effects of lithium treatment in two patients diag-
nosed with ASDs in childhood and presented regression with 
progressive loss of verbal and motor skills, catatonic features, 
aggressive and impulsive behaviors, and sleep disturbances 
after a stressful event during adolescence.217 They both 
presented a mutation/microdeletion of the SHANK3 gene on 
chromosome 22q13.3 that encodes a scaffold protein located 
at the glutamatergic synapses and involved in the regulation 
of the structural organization of dendritic spines and binding 
partner of neuroligins, accounting for approximately 2% 
of cases of intellectual disability in ASDs patients.218 After 
deletion of SHANK3 gene, the nervous system is thought to 
become more susceptible to developmental problems and 
psychiatric disorders, less able to recover after psychiatric 
and somatic events and more vulnerable to degeneration in 
the long term.219 Various psychotropic medications admin-
istered to the two patients (antipsychotics, benzodiazepines, 
antiepileptic drugs, antidepressants, and methylphenidate) 
failed to improve clinical symptoms and led to multiple side 
effects. In contrast, lithium therapy permitted reversibility of 
regression symptoms and catatonic features and the stabiliza-
tion of behavioral disorders without significant side effects,217 
suggesting that SHANK3 patients with ASDs may represent 
a more vulnerable subgroup with an atypical form of BD,219 
in agreement with previous observations.220,221
Finally, lithium use has been explored in preclinical models 
of DS. DS is the leading genetic cause of intellectual disability 
and has been associated to impaired hippocampal neurogen-
esis. This latter plays a key role in establishing functional 
neuronal network and synaptic connectivity. The altered 
synaptic plasticity (eg, excitation/inhibition imbalance) 
discovered in mouse models of DS has been implicated in 
cognitive dysfunctions.143,222–224 Recent studies showed that 
1-month administration of lithium in the Ts65Dn mouse, a 
model of DS, was able to restore adult neurogenesis in the DG 
and subventricular zone to physiological levels by stimulating 
the proliferation of neuronal precursor cells through the phar-
macological activation of the Wnt/β-catenin pathway.143,153 
The restoration of adult neurogenesis completely rescued the 
synaptic plasticity of newborn neurons in the DG and led to 
the full recovery of behavioral performance in three distinct 
hippocampal-dependent cognitive tasks (contextual fear con-
ditioning, object location, and novel object recognition).143
Lithium in cerebral traumatic/
ischemic injury
Emerging evidence from preclinical research suggests that 
lithium can mitigate neurological deficits incurred from 
traumatic or ischemic brain injury.40,70
The pathophysiology of TBI, after an initial mechanical 
injury that damages neurons, glia, and vascular structures, 
includes a cascade of secondary events that finally lead to neu-
rodegeneration and loss of neurological functions: oxidative 
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stress; excitotoxicity via excess glutamate release; increased 
NMDAR activation; neuroinflammation via proinflammatory 
cytokines, NO, or prostaglandins; mitochondrial disruption; 
failure of the blood–brain barrier (BBB) involving cere-
bral edema, hypoxia, and ischemia; and cellular death via 
necrosis and caspase-dependent (caspase-3) and/or caspase-
independent apoptosis.70,225,226 Neuropsychiatric sequelae 
such as depression, anxiety, and PTSD and behavioral and 
cognitive deficits accompany secondary injuries.70 Patients 
afflicted by TBI show increased memory impairment, and 
increasing evidence suggests that TBI is a major risk factor 
for the development of AD.227–229
Given the neuroprotective effects of lithium, recent 
research has investigated its putative use in preclinical stud-
ies on TBI paradigms.70 Lithium pretreatment was found 
to attenuate interleukin-1β expression, brain edema, hip-
pocampal neurodegeneration, and loss of hemispheric tissues, 
improve memory and spatial learning, and alleviate depres-
sive behaviors in mouse models of mild TBI.230,231 Postinjury 
injections with therapeutic doses of lithium also reduced 
lesion volume and attenuated TBI-induced neuroinflamma-
tion by inhibiting microglia activation and cyclooxygenase-2 
induction, while BBB integrity was maintained through the 
inhibition of matrix metallopeptidase-9 expression. TBI-
induced hyperlocomotor activity, anxiety-like behaviors, 
and impairments in motor coordination were all normalized 
by lithium treatment. In addition, GSK-3β phosphorylation 
was found to be robustly increased after postinjury adminis-
tration of lithium, with subsequent β-catenin accumulation, 
and reduced neuronal loss in the hippocampal CA3 region, as 
well as decreased hippocampal-dependent deficits in learning 
and memory.70,232,233
Similarly, GSK-3β has been strongly implicated in the 
pathogenesis of neuronal death caused by ischemic injury. 
While GSK-3β, in preclinical models of transient focal cere-
bral ischemia, was found to be activated inducing apoptotic 
cell death, its inactivation shortly after permanent focal or 
global cerebral ischemia was found to promote survival of 
vulnerable neurons, thus identifying GSK-3β inhibition as 
a major target for treatments.49
Pretreatment with lithium and valproate was found to 
attenuate the hypoxia-induced serine dephosphorylation of 
GSK-3α and GSK-3β in mouse cerebral cortex, hippocam-
pus, and striatum.234 Consistently, in a model of neonatal rat 
hypoxic–ischemic brain injury, postinsult treatment with 
lithium therapeutic doses reduced the ischemia-induced 
dephosphorylation of GSK-3β and the extracellular signal-
regulated kinase, the activation of calpain and caspase-3, the 
mitochondrial release of cytochrome c and apoptosis-inducing 
factor, as well as autophagy.128 Lithium inhibition of GSK-3β 
is also accompanied by the upregulation of Bcl-2, increase in 
the DNA-binding activity of heat shock factor-1 to the heat-
shock element, thus superinducing Hsp70, downregulation of 
p53, and decreased expression of Bcl-2-associated X protein 
in rat models of stroke.235–238 These findings highlight the 
prominent role of GSK-3β inhibition in the antiapoptotic 
effects of lithium under ischemic conditions.
Besides the inhibition of GSK-3, lithium showed to pro-
vide neuroprotection in rat hippocampus following cerebral 
ischemia through the downregulation of NMDAR function, 
overstimulated as a consequence of the glutamate extracel-
lular accumulation.122
Long-term lithium pretreatment at therapeutically rel-
evant doses decreased brain infarct volume and apoptotic 
cell death and improved neurological deficits in a perma-
nent rat model of brain focal ischemia.238,239 Moreover, it 
prevented ischemia-induced exploratory behavioral changes 
and memory impairments in an animal model of global 
cerebral ischemia.235 These benefits were associated with 
an increase in the number of viable cells and a decrease in 
apoptotic cells in the CA1 hippocampal area of ischemic 
brain. Infarct volume, neurological deficits, and the number 
of neurons showing DNA damage in the ischemic brain were 
also reduced by postinsult subcutaneous injection of lithium 
at 0.5 mEq/kg in a rat ischemia/reperfusion model.237
Lithium has been demonstrated to inhibit neuroinflam-
mation resulting from ischemic brain injury by preventing 
inflammatory disorder of the hematoencephalic barrier 
and neurodegeneration.233 Long-term lithium treatment of 
neonatal rats subjected to hypoxic–ischemic brain injury 
significantly reduced total tissue loss, at least partly by 
inhibiting microglia activation and attenuating proinflam-
matory cytokines (ie, interleukin-1β) or chemokine levels.157 
Overexpression of Hsp70, leading to the inactivation of the 
inflammatory transcription factor NF-κB,240 has been pro-
posed as a possible mechanism by which lithium exerts its 
anti-inflammatory activity in experimental stroke models.
The stimulation of hippocampal neurogenesis has also 
been implicated in the neuroprotective effect of lithium 
against brain ischemia.157,158 In addition, lithium treatment 
showed to improve stroke recovery in rats by augmenting 
neurovascular remodeling and vascular neoformation.241 
Specifically, it was found to increase the VEGF protein 
levels via a mechanism involving the PI3-kinase and GSK-3 
signaling pathways in cultured rat brain endothelial cells.109 
Since VEGF has been linked to angiogenesis, neurogenesis, 
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and neuroprotection,242 this growth factor signaling 
mechanism may contribute to lithium’s reported ability to 
promote neurovascular remodeling after ischemic stroke.
Finally, studies on mesenchymal stem cells in rat models 
of brain ischemia showed that incubation with lithium 
chloride increased their migratory ability and homing to dam-
aged tissues, reduced infarct volume, enhanced regenerative 
potential and angiogenesis in the infarcted penumbra regions, 
and improved functional recovery.243,244
Conclusion
Increasing evidence highlights BD, as well as other neu-
ropsychiatric conditions, to be associated with morpho-
logical brain abnormalities, such as regional impairments 
in neuroplasticity, cellular resilience, and hippocampal 
neurogenesis, which highlight the role of neurodegenera-
tion in BD. This new perspective has induced most recent 
research to focus on the possible neuroprotective effects of 
psychotropic medications, particularly those whose efficacy 
in the treatment of BD has been corroborated.9–11,13–15,20,245 
Consistently, over the past few years, increasing promising 
results have emerged for lithium salts, a medication histori-
cally used to treat BD.
Since the GSK-3, the main target of lithium, plays a key 
role in the pathogenesis of many neuropsychiatric disorders, 
the therapeutic potentials of lithium have been investigated in 
various preclinical paradigms of different neurodegenerative 
diseases associated with cell atrophy/loss and impairment 
of cellular resilience, as well as, most recently, of neurode-
velopmental disorders.49,117,246–248 There is now evidence that 
the neuroprotective benefits of this agent in the human brain 
are exerted through several complementary mechanisms 
leading to increased neuronal viability/function, enhanced 
angiogenesis and neurogenesis, BBB integrity maintenance, 
and anti-inflammation as well as disease-specific neuropro-
tective properties.10 Thus, the findings reported in the pres-
ent review provide intriguing support for the neurotrophic/
neuroprotective effects of chronic treatment with lithium, 
suggesting possible implications for its use in other neurop-
sychiatric conditions, including those neurodevelopmental 
disorders, such as ASD, recently suggested as the possible 
common vulnerability factor for most mental disorders.249,250 
The encouraging results reported so far suggest the need for 
further studies exploring the new therapeutic potentials of 
this old drug in clinical samples.
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